The Latest Breaking News from Obesity

Humans have been processing food for thousands of years. While some processing can increase food’s safety and shelf-life, consuming lots of ultra-processed foods (UPFs) is linked to health issues such as obesity, high blood pressure, heart disease and type 2 diabetes.

If you’ve ever tried to lose weight, you may have experienced one of these popular pitfalls.

Exclusive: As a London event promotes surgical tourism packages, experts call for advertising controls

Every family needs groceries, and most people regularly venture to the supermarket to gather supplies. If researchers can help shoppers make healthier choices, we can improve the obesity problem in a simple yet effective way. But until recently, nobody really understood what motivated people to choose certain products – we…

UPFs have been linked to poor health, such as through an increased risk of obesity and heart disease

According to the World Obesity Atlas, 42% of the global population will be overweight or obese in 2025. Lack of physical activity is one of the primary causes. Experts regard this as a serious health problem and in Greco-Roman times, too, doctors thought being overweight was bad for one’s health.

Pfizer's stock presents a compelling investment opportunity, trading at an attractive valuation with a high dividend yield, as the company makes promising progress on its oral obesity drug, danuglipron, in a market dominated by injectable treatments.

With so much health advice to avoid excessive sugar in our diets to reduce risks obesity and tooth decay, some people choose to use artificial sweeteners as an alternative in hot drinks and recipes.

Obesity increases the risk of developing a number of cancers, so it stands to reason that drugs that reduce body weight should also reduce the risk of developing these cancers.

Cancer doctors know better than anyone how you can give yourself the best possible chance of avoiding a disease that one in two of us will get. Here, they share the tips that they live by

With strong first-quarter results and promising growth in its diabetes and obesity treatments, all eyes are on Novo Nordisk’s (NVO) to see if the pharmaceutical giant can maintain its momentum. Will the upcoming second-quarter earnings report reflect its market potential? Learn more to find out….